GLP-1 use linked to 34.5% lower one-year atrial fibrillation risk in CKD
Ventricular tachyarrhythmias and all-cause hospitalization were also lower in the treated cohort, with benefits persisting through two and three years of follow-up.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 16 20:00 ETSource: International journal of cardiology
The wire
- 01A TriNetX target trial emulation across 66 health systems matched 7,326 non-diabetic adults with obesity and CKD stage 3-5 on semaglutide, liraglutide or tirzepatide against 7,326 untreated; one-year incident AF was 1.63% versus 2.62% (HR 0.655).
- 02Reductions held for paroxysmal, persistent and longstanding persistent AF, and hospitalization fell (HR 0.668), pointing clinicians toward a cardiorenal phenotype that may warrant closer attention.
- 03This is a retrospective claims-based cohort, not a randomized trial; permanent AF was non-significant at one year and the authors call for dedicated randomized studies.
From the source
Read at pubmed.ncbi.nlm.nih.govGLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study
International journal of cardiology · 2026 Oct 17 · Hassan A, Okorigba E, Grace C et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42892471/
